

23 May 2007

To All Pharmaceutical Suppliers, Medical Groups and Interested Parties

Proposal to amend restrictions for various pharmaceuticals in Section B of the Pharmaceutical Schedule

PHARMAC is proposing to amend the restrictions currently applying to amantadine hydrochloride, apomorphine hydrochloride, clobazam tab, entacapone and selegiline hydrochloride tab 5 mg in Section B of the Pharmaceutical, with effect from 1 August 2007. We are now seeking feedback on this proposal. Proposed amendments are as follows (proposed deletions in strikethrough):

Amantadine hydrochloride

AMANTADINE HYDROCHLORIDE —~~Retail pharmacy Specialist~~
Cap 100 mg

Apomorphine hydrochloride

APOMORPHINE HYDROCHLORIDE —~~Hospital pharmacy [HP3] Specialist~~
Inj 10 mg per ml, 1 ml

Clobazam

CLOBAZAM —~~Retail pharmacy Specialist~~
Tab 10 mg

Entacapone

ENTACAPONE —~~Retail pharmacy Specialist~~
Tab 200 mg

Selegiline hydrochloride

SELEGILINE HYDROCHLORIDE —~~Retail pharmacy Specialist~~
Tab 5 mg

If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by **5:00 pm, 8 June 2007**. All comments submitted by this date will be considered.

Yours sincerely



Geraldine MacGibbon
Therapeutic Group Manager